IP Library Granted Patent US 8,377,470
Granted Patent B2
US 8,377,470 · App. 13/543,244 · Granted Feb 19, 2013

Non-gelatin soft capsule system

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,377,470
App. No.
13/543,244
Granted
Feb 19, 2013
Kind
B2
Abstract

A non-gelatin encapsulation system for liquid filled soft capsules, by nature of the carrier, the cationic-ionic balance of the carrier and the active ingredients, or the concentration of the active ingredients and excipients, are difficult or impossible to commercially encapsulate in gelatin capsules. In particular, the system is adapted for the encapsulation of highly basic, or alkaline, fills. The system provides for a predominantly starch and gelling carrageenan based shell, which displays high resistance to both concentrated fills and to alkaline fills, in particular, to those fills which contain the salt or salts of weak acids and strong bases.

Claims (38)

1. A non-gelatin soft capsule system for encapsulating chemical compounds, said non-gelatin soft capsule system comprising:

a shell comprising a modified starch or a native potato starch and a gelling carrageenan, wherein the weight to weight ratio of starch to gelling carrageenan is between 1.5 to 1 and 5 to 1; and

a fill, said fill comprising:

at least one active ingredient dissolved or dispersed in at least one carrier,

wherein the fill has a pH greater than 7.5,

wherein the shell exhibits resistance to degradation caused by alkaline fills,

wherein said shell further comprises water, a plasticizer and a buffer, and

wherein said gelling carrageenan comprises kappa-carrageenan.

2. A non-gelatin soft capsule system for encapsulating chemical compounds, said non-gelatin soft capsule system comprising:

a shell comprising a modified starch or a native potato starch and a gelling carrageenan, wherein the weight to weight ratio of starch to gelling carrageenan is between 1.5 to 1 and 5 to 1; and

a fill, said fill comprising:

at least one active ingredient dissolved or dispersed in at least one carrier,

wherein the fill has a pH greater than 7.5,

wherein the shell exhibits resistance to degradation caused by alkaline fills,

wherein said shell further comprises water, a plasticizer and a buffer, and

wherein said gelling carrageenan comprises a mixture of iota-carrageenan and kappa-carrageenan.

3. A non-gelatin soft capsule system for encapsulating chemical compounds, said non-gelatin soft capsule system comprising:

a shell comprising a modified starch or a native potato starch and a gelling carrageenan, wherein the weight to weight ratio of starch to gelling carrageenan is between 1.5 to 1 and 5 to 1; and

a fill, said fill comprising:

acetaminophen dissolved or dispersed in at least one carrier, and

an alkali agent sufficient to partially neutralize a portion of said acetaminophen by forming an equilibrium between (1) said acetaminophen and (2) the salt of said acetaminophen and said alkali agent,

wherein the fill has a pH greater than 7.5, and

wherein the shell exhibits resistance to degradation caused by alkaline fills.

4. The non-gelatin soft capsule system according to claim 3 , wherein said acetaminophen is present in the non-gelatin soft capsule system in a weight to weight ratio of at least 40%.

5. A non-gelatin soft capsule system for encapsulating chemical compounds, said non-gelatin soft capsule system comprising:

a shell comprising a modified starch or a native potato starch and a gelling carrageenan, wherein the weight to weight ratio of starch to gelling carrageenan is between 1.5 to 1 and 5 to 1; and

a fill, said fill comprising:

naproxen dissolved or dispersed in at least one carrier, and an alkali agent sufficient to partially neutralize a portion of said naproxen by forming an equilibrium between (1) said naproxen and (2) the salt of said naproxen and said alkali agent,

wherein the fill has a pH greater than 7.5, and

wherein the shell exhibits resistance to degradation caused by alkaline fills.

6. The non-gelatin soft capsule system according to claim 5 , wherein said naproxen is present in the non-gelatin soft capsule system in a weight to weight ratio of at least 20%.

7. A non-gelatin soft capsule system for encapsulating chemical compounds, said non-gelatin soft capsule system comprising:

a shell comprising a modified starch or a native potato starch and a gelling carrageenan, wherein the weight to weight ratio of starch to gelling carrageenan is between 1.5 to 1 and 5 to 1; and

a fill, said fill comprising:

at least one active ingredient dissolved or dispersed in at least one carrier,

wherein the fill has a pH greater than 7.5, and

wherein the shell exhibits resistance to degradation caused by alkaline fills,

wherein said at least one active ingredient is selected from the group consisting of pseudoephedrine hydrochloride, dextromethorphan hydrobromide, doxylamine succinate, guaifenesin, diphenhydramine, aspirin, caffeine, ranitidine, cimetidine, celecoxib, ritonavir, fexofenadine, and combinations thereof.

Assignments (3)
RELEASE OF SECURITY INTEREST IN PATENT COLLATERAL (049221/0673) Recorded Dec 19, 2024
From: JPMORGAN CHASE BANK, N.A.
To: CATALENT PHARMA SOLUTIONS, LLC; R.P. SCHERER TECHNOLOGIES, INC.; R.P. SCHERER TECHNOLOGIES, LLC; REDWOOD BIOSCIENCE, INC.
Reel/Frame 069751/0100 →
SECURITY INTEREST Recorded Dec 19, 2024
From: CATALENT CTS (KANSAS CITY), LLC; REDWOOD BIOSCIENCE, INC.; R.P. SCHERER TECHNOLOGIES, LLC; CATALENT WELLNESS, LLC; CATALENT PHARMA SOLUTIONS, INC.; CATALENT WELLNESS NEW JERSEY, LLC; CATALENT MARYLAND, INC.; CATALENT GREENVILLE, INC.; CATALENT MICRON TECHNOLOGIES, INC.; CATALENT SAN DIEGO, INC.; CATALENT WELLNESS VIRGINIA, LLC; CATALENT USA PACKAGING, LLC; CATALENT PHARMA SOLUTIONS, LLC
To: ARES CAPITAL CORPORATION, AS COLLATERAL AGENT
Reel/Frame 069743/0458 →
SUPPLEMENTAL SECURITY AGREEMENT Recorded May 20, 2019
From: R.P. SCHERER TECHNOLOGIES, LLC; CATALENT PHARMA SOLUTIONS, LLC; REDWOOD BIOSCIENCE, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 049221/0673 →